Answers are grounded in this paper and cite their sources.
Cohort study investigates surgical staging's impact on prognosis in high-risk endometrial cancer, suggesting its importance.
The prognostic relevance of surgical staging in patients with high-intermediate-risk and high-risk endometrial cancer remains uncertain. In this cohort study, we investigated the prognostic role of robot-assisted laparoscopic staging surgery among patients with clinically early-stage endometrial carcinoma at a high-intermediate-risk or high-risk for recurrence. Clinical data of women with clinically International Federation of Gynaecology and Obstetrics (FIGO) 2009 stage I–II, grade 3 endometrioid or non-endometrioid EC who were intended to undergo robot-assisted laparoscopic staging surgery were retrospectively collected from a single tertiary referral center. The procedure consisted of total hysterectomy with bilateral salpingo-oophorectomy, pelvic lymphadenectomy, and, when feasible, para-aortic lymphadenectomy, with additional omentectomy and peritoneal biopsies performed in a subset of cases. Survival outcomes were assessed using Kaplan–Meier analysis, with additional subgroup analyses by histological subtype. A total of 166 patients, of which 154 patients (92.8%) with FIGO 2009 stage I and 12 patients (7.2%) with FIGO 2009 stage II were included, comprising various histological subtypes, including 64 (38.6%) with endometrioid carcinoma, 52 (31.3%) with serous carcinoma, 11 (6.6%) with clear cell carcinoma, and 27 (16.3%) with carcinosarcoma. Thirty-two patients (19.3%) were reclassified as having FIGO stage disease III–IV based on final pathology. The 5-year disease-specific survival was 25.5% for upstaged patients compared with 73.1% for those who were not upstaged. Robot-assisted laparoscopic staging provides valuable prognostic information in clinically early-stage endometrial cancer with a high-intermediate-risk or high-risk of recurrence. These findings underscore the value of surgical staging in informing prognosis and guiding adjuvant treatment decisions.
No takes yet. Share an insight, caveat, or question.
Jong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: